ArticleFrontiers in endocrinology2026
SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To investigate the association between sodium-glucose cotransporter 2 inhibitors (SGLT2i) use and diabetic retinopathy (DR) progression, and to explore supporting genetic and molecular evidence using a retrospective cohort study with Mendelian randomization (MR). Materials and methods: In this retrospective cohort study at Shandong Provincial Hospital from January 2023 to December 2024, patients with type 2 diabetes on stable SGLT2i plus basal insulin (SGLT2i+INS) or sulfonylureas plus basal insulin (SUL+INS) were included. Wide-field swept-source optical coherence tomography angiography (SS-OCTA) was used to assess retinal microvascular parameters. Kaplan-Meier and Cox regression analyses evaluated DR progression and new-onset diabetic macular edema with sensitivity analyses performed to assess robustness. An exploratory nomogram was developed and evaluated by decision curve analysis. Two-sample MR and two-step mediation analyses were conducted to examine the genetic association between SGLT2 and DR and to identify potential mediating metabolites and plasma proteins. Results: A total of 191 eyes were included: 56 in the SGLT2i+INS group and 135 in the SUL+INS group. SGLT2i+INS was associated with a lower risk of DR progression (HR = 0.40, 95% CI 0.19-0.84; P = 0.016) and reduced cumulative incidence (log-rank P = 0.032). The exploratory OCTA-based nomogram showed modest performance (C-index=0.705). MR supported an association between genetically proxied SGLT2 and DR risk (OR = 1.21, 95% CI 1.05-1.39; P = 0.009). Nine metabolites and five plasma proteins showed nominal evidence of potential mediation. Conclusions: Among insulin-treated patients with type 2 diabetes, SGLT2i use was associated with a lower risk of DR progression than sulfonylurea use. OCTA parameters and candidate molecular mediators may provide exploratory prognostic and biological insights, warranting validation in larger prospective studies and randomized trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.